Glaxosmithkline | Des Atouts



Assets Changement Date
AbbVie USD 135.16B 8.26B 2024-12
Amgen USD 91.84B 956M 2024-12
AstraZeneca USD 104.04B 887M 2024-12
Aurora Cannabis CAD 866.52M 57.75M 2024-12
Bausch Health Companies USD 26.54B 45M 2024-09
Bristol-Myers Squibb USD 92.6B 1.07B 2024-12
Canopy Growth CAD 1.16B 68.13M 2024-12
Corcept Therapeutics USD 840.55M 56.3M 2024-12
Drreddys Laboratories INR 481.06B 15.1B 2024-12
Eli Lilly USD 78.71B 3.11B 2024-12
GlaxoSmithKline GBP 59.46B 1.41B 2024-12
Glaxosmithkline GBP 59.46B 1.41B 2024-12
Indivior 1.46B 71M 2024-09
J&J USD 180.1B 1.82B 2024-12
Merck USD 117.11B 426M 2024-12
Novartis USD 102.25B 1.28B 2024-12
Pacira USD 1.55B 31.82M 2024-12
Perrigo USD 9.65B 1.56B 2024-12
Pfizer USD 213.4B 6.08B 2024-12
Prestige Brands USD 3.33B 12.61M 2024-12
Roche Holding CHF 101.8B 6.02B 2024-12
Sanofi 129.76B 3.29B 2024-06
Supernus Pharmaceuticals USD 1.37B 25.37M 2024-12
Takeda JPY 15.11T 533.85B 2024-12
Teva Pharmaceutical Industries USD 39.33B 2.43B 2024-12
Zoetis USD 14.24B 120M 2024-12



Glaxosmithkline Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.